Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA DTC Guideline Compliance Could Avert Plaintiff, DoJ Backlash – Troy

Executive Summary

Responding to warning and untitled letters from FDA's Division of Drug Marketing, Advertising & Communications could help to shield firms in the event of product liability suits, according to former FDA Chief Counsel Daniel Troy
Advertisement

Related Content

Peer-Reviewed Uncontrolled Trials Valid For Drug Promotions, WLF Says
Peer-Reviewed Uncontrolled Trials Valid For Drug Promotions, WLF Says
PhRMA DTC Principles Compliance To Get Independent Panel Review In 2007
PhRMA DTC Principles Compliance To Get Independent Panel Review In 2007
FDA DTC Enforcement Regs Need Overhaul, Former Chief Counsel Troy Says
Vioxx DTC Ads Consistent With “Learned Intermediary” Defense, Merck Says
FDA Releases DTC Guidances; “Not The Last Word” On Ads, McClellan Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS046336

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel